CDNA logo

CDNA
Caredx Inc

3,209
Mkt Cap
$1.13B
Volume
691,822.00
52W High
$23.24
52W Low
$10.96
PE Ratio
-141.60
CDNA Fundamentals
Price
$21.82
Prev Close
$21.44
Open
$21.40
50D MA
$18.82
Beta
1.51
Avg. Volume
810,065.79
EPS (Annual)
-$0.4007
P/B
3.57
Rev/Employee
$496,477.12
$852.92
Loading...
Loading...
News
all
press releases
CareDx (NASDAQ:CDNA) Upgraded to Strong-Buy at Wall Street Zen
Wall Street Zen raised shares of CareDx from a "buy" rating to a "strong-buy" rating in a research note on Sunday...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA), The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Business Wire·9d ago
News Placeholder
CareDx (NASDAQ:CDNA) Trading Down 8.7% - What's Next?
CareDx (NASDAQ:CDNA) Trading Down 8.7% - Here's What Happened...
MarketBeat·11d ago
News Placeholder
CareDx Q1 Earnings Call Highlights
CareDx (NASDAQ:CDNA) reported first-quarter 2026 results showing faster growth in its core testing and patient services businesses, while outlining two major portfolio moves: the pending divestiture...
MarketBeat·12d ago
News Placeholder
CareDx (NASDAQ:CDNA) Releases Earnings Results, Beats Estimates By $0.21 EPS
CareDx (NASDAQ:CDNA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of...
MarketBeat·12d ago
News Placeholder
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
CareDx (CDNA) delivered earnings and revenue surprises of +209.09% and +7.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Business Wire·12d ago
News Placeholder
CareDx Announces First Quarter 2026 Financial Results
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Business Wire·12d ago
News Placeholder
CareDx (CDNA) Q2 2025 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·12d ago
News Placeholder
CareDx, Inc. (NASDAQ:CDNA) Given Average Rating of "Hold" by Brokerages
Shares of CareDx, Inc. (NASDAQ:CDNA - Get Free Report) have received a consensus rating of "Hold" from the eight research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have gi...
MarketBeat·14d ago
<
1
2
...
>

Latest CDNA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.